Perirenal hematoma in a patient treated with bevacizumab for metastatic colon cancer: A case report

被引：1

作者：

Lee, Min Sung ^{[1
]}

Shin, Il Sang ^{[1
]}

Kwun, Do Hyung ^{[1
]}

Kim, Se Hyung ^{[1
]}

Kim, Hyun Jung ^{[1
]}

Kim, Chan Kyu ^{[1
]}

Park, Seong Kyu ^{[1
]}

Hong, Dae Sik ^{[1
]}

Yun, Jina ^{[1
]}

机构：

[1] Soonchunhyang Univ, Sch Med, Dept Internal Med, Div Hematol Oncol,Bucheon Hosp, 1174 Jung Dong, Bucheon 420767, Gyeonggi, South Korea

来源：

ONCOLOGY LETTERS | 2016年 / 11卷 / 05期

关键词：

hematoma; bevacizumab; colonic neoplasms; ENDOTHELIAL GROWTH-FACTOR; METAANALYSIS; HEMORRHAGE; SAFETY;

D O I：

10.3892/ol.2016.4328

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The present study reports the case of a patient that developed spontaneous perirenal hematoma during treatment with bevacizumab-containing chemotherapy. A 44-year-old woman with metastatic sigmoid colon cancer, who was being treated with bevacizumab (5 mg/kg, intravenous, 90 min biweekly), was admitted to hospital following 3 cycles of chemotherapy, with a sudden onset of dyspnea and oliguria. An emergency hemodialysis was performed and a large right perirenal hematoma was diagnosed using computed tomography. The patient was immediately instructed to discontinue chemotherapy, including bevacizumab. However, the right perirenal hematoma increased in size and a left perirenal hematoma developed 3 weeks later. The two perirenal hematomas stabilized 7 weeks subsequent to the termination of bevacizumab treatment. Spontaneous perirenal hematoma due to bevacizumab treatment is an extremely rare occurrence. However, physicians should be aware of this potential complication associated with bevacizumab treatment.

引用

页码：3210 / 3212

页数：3

共 14 条

[1] ACQUIRED CYSTIC-DISEASE OF KIDNEYS - HAZARD OF LONG-TERM INTERMITTENT MAINTENANCE HEMODIALYSIS [J].